LONG-DES VI (Drug Eluting Stent for Long Lesions in Coronary Artery)

Inclusion Criteria: * Age more than 20 years * Significant native coronary artery stenosis (\> 50% by visual estimate) with lesion length of more than 50mm, which requires at least 2 multiple long stent placement without intervening normal segment * Patients with silent ischemia, stable or unstable angina pectoris, and Non-ST-elevation myocardial infarction (NSTEMI) * The patient or guardian agrees to the study protocol and the schedule of clinical and angiographic follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the respective clinical site Exclusion Criteria: * Any contraindication to any of the following medications: aspirin, heparin, clopidogrel, stainless steel, contrast agents, zotarolimus, or everolimus * An elective surgical procedure is planned that would necessitate interruption of antiplatelet drugs during the first 6 months post enrollment * Acute ST-segment-elevation MI or cardiogenic shock * Terminal illness with life expectancy \< 1 year * Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period * In-stent restenosis at target vessel (either bare metal stent or drug-eluting stent segment) However, non-target vessel In-stent restenosis is permitted * Patients with EF \< 30% * Serum creatinine level \>=2.0mg/dL or dependence on dialysis * Patients with left main stem stenosis (\> 50% visual estimate)